Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings Inc (RANI) is a clinical-stage biotherapeutics leader developing oral alternatives to injectable biologic medications through its patented RaniPill technology. This page provides investors and industry observers with timely updates on corporate milestones, clinical trial progress, and strategic initiatives shaping the future of non-invasive drug administration.
Access official press releases, financial disclosures, and third-party analysis covering RANI's advancements in transforming treatments for chronic diseases. Key updates include trial results for oral biologic formulations, intellectual property developments, partnership announcements with pharmaceutical collaborators, and quarterly performance reports.
Bookmark this page for streamlined tracking of RANI's progress in addressing critical challenges in drug delivery. Return regularly to monitor how the company's capsule-based technology could impact treatment adherence, patient comfort, and the broader $500B+ biologics market.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company focusing on oral delivery of biologics and drugs, has announced its participation in two upcoming investor conferences in August 2024. The company will attend the BTIG Virtual Biotechnology Conference on August 5th-6th, participating in one-on-one investor meetings. Additionally, Rani will present at the Canaccord 44th Annual Growth Conference in Boston on August 13th at 3:30 PM ET, featuring a company presentation by CEO Talat Imran and investor meetings.
Interested parties can access live webcasts of these events through the 'Events' section of Rani Therapeutics' website. Webcast replays will be available after the presentations conclude.
Rani Therapeutics Holdings (Nasdaq: RANI), a clinical-stage biotherapeutics company, has announced a $10.0 million registered direct offering. The offering includes 2,800,000 shares of Class A common stock and pre-funded warrants for 446,753 shares, along with Series A and B common warrants. Each share or pre-funded warrant is sold with one Series A and one Series B warrant at $3.08. The warrants have an exercise price of $3.08 and will be exercisable after 6 months. Series A warrants expire in 18 months, while Series B warrants expire in 5.5 years. Maxim Group is the sole placement agent. The offering is expected to close around July 23, 2024, subject to customary conditions.
Rani Therapeutics announced a partnership with ProGen to develop RT-114, an oral obesity treatment using RaniPill® capsules and ProGen's dual agonist, PG-102. The collaboration features a 50/50 cost and revenue share, with Rani leading development in the US, Europe, Canada, and Australia, while ProGen heads efforts elsewhere. The RT-114 program aims to offer a weekly oral dose, potentially improving patient adherence and therapeutic effects. Previous clinical studies of both the RaniPill® platform and PG-102 have shown promising results in bioavailability and safety profiles.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, announced participation in two investor conferences in May 2024. The H.C. Wainwright 2nd Annual BioConnect Investor Conference will be held on May 20th at Nasdaq Headquarters, New York City, featuring a fireside chat and 1x1 investor meetings with CEO Talat Imran. The UBS Spring Biotech Conference will take place on May 21st at UBS, New York City, consisting of 1x1 investor meetings. Live webcast for the H.C. Wainright Conference will be available on Rani's website.
Rani Therapeutics, a clinical-stage biotherapeutics company, will present clinical and preclinical data on their oral delivery platform, the RaniPill® capsule, at Digestive Disease Week 2024. The data will focus on the oral delivery of an Ustekinumab biosimilar, showcasing high bioavailability in healthy human participants and canines. The presentations will take place virtually and in-person on May 18-21, 2024, in Washington, DC.
Rani Therapeutics reported positive topline results from a Phase 1 study for RT-111, an oral anti-Interleukin 12/23 antibody, and plans to initiate a Phase 2 clinical trial for RT-102 for osteoporosis treatment in 2024. The company's RaniPill HC is set for potential Phase 1 trials later in 2024. Financially, Rani Therapeutics had $39.6 million in cash, cash equivalents, and marketable securities as of March 31, 2024, with a decrease in research and development expenses compared to the previous year.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
